Utilizing contraception is critical in preventing unintended pregnancies among obese women. However, clinicians and obese patients may be unclear about which contraceptive methods are optimal. This review discusses the literature on any weight gain associated with contraceptive use, contraceptive efficacy among obese women, and special considerations for contraceptive method selection for women after bariatric surgery. The review also covers new findings on oral emergency contraception and obesity.
Introduction
Approximately 51% pregnancies in the United States each year are unintended. 1, 2 It is likely that many of these unintended pregnancies are among obese women, as obesity is significantly associated with contraceptive nonuse. 3 Women with a body mass index (BMI) >35 kg/m 2 are less likely to use contraceptives than women with a BMI <25 kg/m 2 . 4 Unintended pregnancy in obese women is especially worrisome because of the higher pregnancy risks associated with obesity. 5 Maternal risks include a higher rate of cesarean section, gestational hypertension, gestational diabetes, and preeclampsia. [5] [6] [7] Fetal risks include macrosomia, stillbirth, neural tube defects, orofacial defects, cardiac anomalies, and hydrocephalus. 8, 9 In addition, infants born to obese mothers also have long-term sequelae of childhood obesity and type 2 diabetes. 10, 11 It is important for clinicians to address family planning needs of obese patients in order to prevent unintended pregnancy and subsequent obstetric complications. Obese women of reproductive age in particular would benefit from contraceptive counseling as they may underestimate their fertility because of oligo-ovulation. In addition, obese women may desire to use contraceptives so they can optimize their weight before conceiving so they can have healthier pregnancies.
Risks of Weight Gain With Hormonal Contraceptives
Obese women may avoid contraceptives because of fear that hormones may contribute further to weight gain. However, most studies have indicated that weight gain with many contraceptive methods is similar to age-related weight gain. 12 www.clinicalobgyn.com | 501 A Cochrane review indicated no relationship between combination oral contraceptives or the patch on weight gain. 12 The relationship between weight gain and progestin-only methods has yielded conflicting results. A Cochrane review found limited evidence of weight gain in only 5 of 16 progestin-only studies. Small changes in weight or body fat percentages were found with depot-medroxyprogesterone (DMPA), norplant, and the levonorgestrel-intrauterine device (LNG-IUD). 13 Studies describing a difference found a weight gain of <2 kg up to 12 months for these methods and a possible increase in body fat and decrease in lean body mass compared with users of non-hormonal contraceptives. 13 Although the study on the LNG-IUD in the review reported a statistically significant small change in body fat percentage, this increase could be attributed to aging. 13 The one contraceptive method that has been most consistently associated with weight gain is DPMA, with a typical gain of about 5 pounds in the first year. 13 Mean weight differences between DPMA and the nonhormonal IUD in a study was 2.28 kg at year 1, 2.71 kg at year 2, and 3.17 kg at year 3. 14 A study on DPMA use postpartum found a weight gain of about 3 to 6 pounds over 1 year of use. Patients who were overweight or obese before pregnancy had an even higher risk for weight gain during this time period. 15 Those with a BMI of 26 to 35 kg/m 2 had an 8.8 pound weight gain from 6 weeks postpartum to 1 year, whereas normal weight women actually lost weight. Although DMPA is a good contraceptive method, other contraceptive options should be considered for women trying to lose weight.
Contraceptive Methods Efficacy in Obese Women
Most of the original studies on contraceptive efficacy excluded obese women from the trials. Several studies have recently demonstrated efficacy of certain contraceptive methods among overweight women. Contraceptive methods such as the intrauterine device theoretically should not be affected by BMI, as the mechanism is largely local. 16 An analysis of the Contraceptive CHOICE Project found that the 3-year failure rates of intrauterine devices (both copper and LNG) in overweight and obese women were <1/ 100 women-years and had no variation by BMI. 16 Thus, both these methods were considered safe and efficacious in obese women. Insertion of an IUD maybe more difficult in obese women because of poor visualization of the cervix and limited assessment of uterine position. In these instances, the use of ultrasound may be helpful. 17 
Combined Estrogen and Progestin Methods
Studies are conflicting regarding the efficacy of oral contraceptives in obese women. A Cochrane review suggests overweight women (BMI>25 kg/m 2 ) are significantly more likely to get pregnant on oral contraceptives. 18 However, some studies have shown that there is no overall difference in failure rates according to BMI and body weight. 19, 20 Although data is conflicting, overall conclusions suggest unintended pregnancy rates among overweight women using oral contraceptives are similar or slightly higher than that among nonoverweight women. 20 Pharmacokinetic (PK) parameters (drug clearance, half-life, AUC, time to reach steady state) of oral contraceptive metabolism were studied in obese women, with no clear conclusions. Overall, all the PK studies have shown different PK parameters for obese women compared with normalweight women, but it is unknown whether these changes are significant for decreased efficacy of oral contraceptives. 21 Several PK studies have suggested increased follicular development for obese women on oral contraceptives whereas some have shown no significant differences in follicular size. 21 A study by Edelman et al 22 correlated PK parameters with end-organ activity (ovarian follicle development by ultrasound, cervical mucus assessment). Although obese women had significant changes in their PK parameters, these changes did not correlate with ovulation.
A study by Westhoff et al 23 investigated the PKs of oral contraceptives containing 30 mcg of ethinyl estradiol (EE) and 150 mcg of LNG. Obese women were found to have a lower area under curve, maximum concentration (Cmax), time needed to reach Cmax, and a statistically significant increased half-life for EE. Therefore, it was theorized that oral contraceptive pills may take longer periods of time to reach a steady state in obese women, jeopardizing the 7day placebo and initiation periods in the typical oral contraceptive cycle. However, twice weekly vaginal ultrasounds were performed for the participants in the study and no difference in ovarian follicular activity by BMI was found. Therefore, the efficacy was maintained in obese women as their minimum concentrations of hormones did not drop below the level needed to prevent ovulation.
The vaginal contraceptive ring, which contains 15 mcg EE and 120 mcg etonogestrel, is also a reasonable option for obese women. 24 Women who use the vaginal ring compared with oral contraceptives or the patch are exposed to lower amounts of estrogen, with more stable and precise serum levels. 24 It has been hypothesized that the ring may offer higher hormone levels for obese women than oral contraceptives because the hormones are absorbed directly into the vaginal mucosa and do not go through the firstpass liver metabolism. 25 There are only a few studies on the efficacy studies of the patch in obese women. One study demonstrated that women weighing >90 kg had a significantly increased failure rate than women weighing <90 kg. 26 However, an analysis from the CHOICE Project showed no increase in failure rate by BMI in users of the patch. 19 
Progestin Methods
The progestin-only contraceptive pill remains an efficacious method among obese women. A recent study of >50,000 women found no association between the efficacy of the progestin-only pill and obesity. 27 Moreover, the progestin-only pill has been shown to not increase the risk of thrombosis or cardiovascular disease, which may make it a safe alternative method for women at risk of thromboembolism. 28 Food and Drug Administration labeling for packaging of the etonogestrel implant states that women who weigh >130% of ideal body weight were not studied in clinical trials and that overweight women may have lower serum concentrations of etonogestrel [NEX-PLANON (etonogestrel implant) HCP, Merck]. This could theoretically mean that the subdermal implant may be less effective in overweight women. Although evidence suggests that the serum etonogestrel concentrations in obese women with the subdermal implant are lower than in normal-weight women, analysis from the CHOICE Project suggests this does not amount to higher failure rates as levels are maintained above the minimal amount needed to prevent ovulation. 16, 29 
Bariatric Surgery
Approximately half of bariatric surgeries are performed among women of reproductive age. 30 The general recommendation for women who undergo bariatric surgery is to wait 1 to 2 years after surgery before attempting to conceive. 31 The American Congress of Obstetricians and Obesity and Contraception 503 www.clinicalobgyn.com Gynecologists (ACOG) recommends postponing pregnancy for at least 12 to 18 months. 32 This recommendation is based on the theoretical risk of malnourishment to the fetus during the rapid weight loss following bariatric surgery. Although this waiting period is the ACOG recommendation, there may be unintended pregnancies during this waiting time because of lack of proper contraceptive use. Many of the women pursuing bariatric surgery are anovulatory and begin ovulating postsurgery as the weight loss can restore ovulatory function in obese women. 33 Therefore, there may be an increase in fertility after these procedures. Changes in body image coupled with increased fertility after surgery may account for a possible increase in unintended pregnancies. 33 Among adolescents who underwent bariatric surgery, the rate of unintended pregnancy was high. One study documented a 12.8% pregnancy rate among adolescent females who underwent gastric bypass surgery, which was more than double the rate among their peers. 34 Contraceptive counseling is therefore especially important for these women.
Often women are not aware that contraceptive options may be limited by bariatric surgery method. One study revealed that only 21% of women from an urban hospital were referred to a gynecologist after bariatric surgery for contraceptive counseling and 16% did not use any contraceptive. 35 Use of long-acting reversible contraception was infrequent, as only 4% of the women used IUDs.
There are only few studies on the effectiveness of hormonal contraceptives in postbariatric surgery patients. On the basis of the existing published literature, the United States Medical Eligibility Criteria for Contraceptive Use (USMEC) does not recommend the use of oral contraceptives among women who have undergone malabsorptive bariatric surgery (Table 1) . 36, 37 Malabsorptive procedures include the jejunoileal bypass, biliopancreatic diversion with or without duodenal switch, and the Roux-en-Y bypass. With these procedures there is concern for decreased absorption of the oral contraceptive with possible impact on efficacy.
Existing studies have suggested that levels of circulating hormones may be lower in postmalabsorptive bariatric surgeries most likely because of decreased intestinal absorption, but the effect on actual contraceptive failure is unclear. 37 One small study showed higher oral contraceptive failure rate for patients postbiliopancreatic diversion. 38 Overall, studies suggest oral contraceptives alone may not be sufficiently reliable for postmalabsorptive surgery patients, but more Categories of medical eligibility criteria for contraceptive use: 1 = a condition for which there is no restriction for the use of the contraceptive method; 2 = a condition for which the advantages of using the method generally outweigh the theoretical or proven risks; 3 = a condition for which the theoretical or proven risks usually outweigh the advantages of using the method; 4 = a condition that represents an unacceptable health risk if the contraceptive method is used.
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Mody and Han www.clinicalobgyn.com research is needed. At present, there is a study funded by the Society of Family Planning further exploring this topic. 39 There are even fewer studies on efficacy of nonoral contraceptive methods in this population. One small study suggested that the etonogestrel-releasing subdermal implant after malabsorptive procedures remains an effective method as serum levels remain above the minimal concentration needed for contraceptive effectiveness. 40 The LNG-IUD is also an acceptable option for women undergoing bariatric surgery. 33 For restrictive bariatric surgery such as lap band and gastric sleeves, all contraceptive methods are acceptable according to the USMEC. 36 Novel pharmacotherapies for weight loss have been developed with limited information on teratogenicity. Effective contraception needs to be addressed by health care professionals who take care of obese patients on certain teratogenic weight loss drugs. Phentermine/topiramate combination therapy has the teratogenic risk of cleft lip with or without cleft palate. 41 Women are required to have a negative pregnancy test before taking the drug but should also use highly effective contraceptives. 41 
Emergency Contraception
One finding that may have a larger societal impact is the publication from Glasier et al 42 indicating that ulipristal acetate is a more effective emergency contraceptive compared with LNG among women with a BMI>25 kg/m 2 . Obese women taking LNG as emergency contraceptive were 4 times as likely to get pregnant than nonobese women taking LNG. Comparatively, obese women taking ulipristal acetate had no statistically significant difference in pregnancy rates compared with nonobese women. 42 
Recommendations
There is still a tremendous need for more research on contraceptive efficacy among this population. More studies are needed on the efficacy of oral contraceptives in obese women, as multiple small trials and limited PK studies show conflicting data [NEXPLANON (etonogestrel implant) HCP, Merck]. 21, [26] [27] [28] [29] Contraceptive trials should include more obese patients. 43 The National Institute of Health has recognized this need and has held a working group around this issue. As clinicians caring for this growing population, it is important that we continue to stay informed of the emerging literature regarding this important topic. Our key recommendations for the clinician managing the obesity and contraception are: (1) Educate obese patients about the obstetrical risk associated with obesity and discuss contraceptive options during weight optimization. (2) Review with all patients that the weight gain with contraception is typically the same as age-related weight gain with a few exceptions. (3) Explain to obese patients that even if some contraceptive methods may be slightly less effective, it is still better to use a contraceptive to prevent unintended pregnancy. (4) For patients who have undergone bariatric surgery, base your contraceptive method on the USMEC guidance. Specifically, avoid oral contraceptives among women who had malabsorptive procedures. (5) For obese women consider using ulipristal acetate as first-line oral emergency contraceptive.
